Ingredient Guide
Hawthorn Berry: Benefits, Dosage, and What the Research Says
Centuries of traditional use, now supported by more than a dozen placebo-controlled clinical trials
Written by Jessica Medson
Hawthorn berry (Crataegus spp.) is a botanical ingredient whose standardized leaf, flower, and berry extracts have been evaluated in more than a dozen placebo-controlled clinical trials, primarily for cardiovascular support. A 2003 meta-analysis of eight trials in 632 patients with mild-to-moderate heart failure found hawthorn extract improved maximal exercise capacity by a mean of 7 Watts over placebo, and a 2025 meta-analysis of six blood pressure trials in 428 participants found a 6.65 mmHg reduction in systolic pressure. The evidence is strongest for adjunctive cardiac performance support; hawthorn should not replace prescribed heart medications and carries meaningful drug interaction potential for anyone on cardiac or antihypertensive therapy.
What Is Hawthorn Berry?
Hawthorn berry comes from shrubs and small trees in the Crataegus genus, a member of the rose family (Rosaceae). Several species are used medicinally, most notably Crataegus monogyna, Crataegus laevigata (sometimes called C. oxyacantha), and Crataegus pinnatifida. The plant grows widely across Europe, North America, and Asia, and its use in supporting heart health is documented across at least 2,000 years of European and traditional Chinese herbal medicine.
Modern supplement preparations typically combine leaves, flowers, and berries, the parts of the plant with the highest concentrations of bioactive polyphenols. The most rigorously studied commercial extract is WS 1442, a water-ethanol extract standardized to 18.75% oligomeric procyanidins (OPCs). This extract appears in the majority of published clinical trials, and the body of evidence is largely specific to it. Not all hawthorn products are standardized to the same constituents or potency, so comparing products by raw berry weight alone can be misleading.
Unlike the majority of botanical supplements, hawthorn has been evaluated in multiple rigorous, placebo-controlled clinical trials enrolling thousands of participants, an unusually large evidence base for a herbal ingredient. Regulatory bodies in Germany have formally recognized Crataegus preparations for supportive use in early-stage heart failure, a distinction shared by very few botanical products.
How Does It Work? The Active Compounds Behind Hawthorn
Bioactive constituents
Hawthorn's cardiovascular activity is attributed primarily to two overlapping classes of polyphenols:78
- Oligomeric procyanidins (OPCs): Potent antioxidant polyphenols that help protect vascular tissue from oxidative stress and appear to contribute to vasodilatory effects.
- Flavonoids: Including vitexin, hyperoside, quercetin, and rutin, these compounds contribute anti-inflammatory, antiplatelet, and vessel-relaxing properties.
Known pharmacological mechanisms
Pharmacological research suggests hawthorn extracts work through several complementary pathways:78
- Positive inotropic effect: Extracts may enhance the force of heart muscle contractions without proportionally increasing oxygen demand, a pharmacological profile that distinguishes hawthorn from conventional inotropic drugs.
- Vasodilation: Hawthorn fractions have been shown to promote release of nitric oxide (NO) from the vascular endothelium, helping blood vessels relax and reducing peripheral resistance.
- Antioxidant protection: The OPC fraction scavenges free radicals and supports endothelial integrity, protecting vessel walls from oxidative damage.
- Antiplatelet activity: Flavonoids may reduce platelet aggregation, supporting healthy blood flow dynamics.
- Anti-inflammatory modulation: Extracts appear to influence inflammatory signaling pathways relevant to vascular health.
It is worth noting an important caveat: a well-designed crossover trial testing doses from 1000 to 2500 mg in 21 prehypertensive adults found no dose-response effect on flow-mediated dilation, a direct measure of NO-driven vasodilation.9 This finding suggests that hawthorn's blood pressure effects, when they occur, may not be primarily driven by the nitric oxide pathway, and that the full mechanism remains incompletely understood.
Cardiac Performance and Heart Failure: What the Clinical Evidence Shows
The most consistent clinical evidence for hawthorn centers on its use as an adjunctive (add-on) therapy in patients with mild-to-moderate chronic heart failure, specifically NYHA functional classes II and III. Multiple randomized, double-blind, placebo-controlled trials have evaluated this application over periods ranging from 8 to 24 weeks. This is studied-population evidence: all participants in these trials were under medical supervision, most were taking standard heart failure medications alongside hawthorn, and results should not be extrapolated to self-treatment of diagnosed cardiac conditions.
What the research shows
A 2003 meta-analysis by Pittler, Schmidt, and Ernst analyzed thirteen randomized, double-blind, placebo-controlled trials and pooled eight of them (632 patients) for quantitative comparison. Treatment with hawthorn extract was associated with a weighted mean improvement of 7 Watts in maximal workload compared with placebo (95% CI: 3 to 11 W; p less than 0.01; n = 310 patients), along with significant reductions in dyspnea, fatigue, and the pressure-heart rate product during exercise.1
Individual trials corroborate this direction of effect. A randomized trial in 143 NYHA class II patients found that those receiving standardized Crataegus berry extract (Crataegisan) for 8 weeks showed a significant 8.3-watt advantage over placebo in exercise tolerance (p = 0.045), with high patient acceptance and tolerability.3 A separate 40-patient trial found that WS 1442 over 12 weeks increased exercise tolerance by 66.3 W x min (10.8%) versus a reduction of 105.3 W x min in the placebo group, with the between-group difference reaching borderline significance (p = 0.06).10 An earlier 8-week study in 30 NYHA II patients also showed statistically significant advantages for WS 1442 over placebo in the pressure-rate product and symptom scores.11
For more advanced (NYHA class III) heart failure, a 16-week trial in 209 patients found that 1800 mg/day WS 1442 produced a statistically significant improvement in maximal tolerated workload compared with both placebo and the lower 900 mg dose, with the higher dose also showing the best tolerability and lowest incidence of dizziness.4
The SPICE trial: a large trial with mixed results
The most ambitious study was the SPICE trial, a 24-month international, placebo-controlled trial enrolling 2,681 patients with NYHA class II-III heart failure on standard care. The primary endpoint, time to first cardiac event, did not reach statistical significance in the overall group (27.9% vs. 28.9%; hazard ratio 0.95; p = 0.476).2 A pre-specified subgroup of patients with relatively preserved left ventricular function (LVEF greater than or equal to 25%) showed a 39.7% reduction in sudden cardiac death (HR 0.59; p = 0.025), but subgroup analyses are hypothesis-generating, not confirmatory, and should be interpreted with appropriate caution.
The bottom line: Multiple smaller trials consistently support hawthorn's ability to help maintain exercise capacity and reduce exertional symptoms in people with mild-to-moderate cardiac dysfunction when used alongside standard care. The SPICE trial did not establish a significant mortality or morbidity benefit in the general heart failure population at 900 mg/day over two years. Hawthorn in this context should be considered a supportive adjunct, not a substitute for prescribed cardiac therapy.
Blood Pressure Support: What the Studies Show
A growing body of controlled research suggests hawthorn extract may help support blood pressure already within the normal range, though the data are more modest and less consistent than the heart failure literature.
What the research shows
A 2025 meta-analysis of six randomized, placebo-controlled trials in 428 participants found that hawthorn supplementation was associated with a statistically significant reduction in systolic blood pressure of 6.65 mmHg (95% CI: -11.72 to -1.59) compared with placebo, across treatment durations of 10 weeks to 6 months and dosages of 250 to 1200 mg/day.5 The accompanying diastolic blood pressure reduction (-7.19 mmHg) did not reach statistical significance, and the authors called for larger, better-designed trials to establish optimal dosing and duration protocols.
An earlier pilot RCT in 36 mildly hypertensive adults given 500 mg hawthorn extract daily for 10 weeks found a promising but non-significant trend toward reduced resting diastolic blood pressure (p = 0.081), with the modest sample size limiting the study's statistical power.6 The researchers described the findings as preliminary and warranting follow-up.
A crossover trial testing doses of 1000, 1500, and 2500 mg in 21 prehypertensive adults found no statistically significant dose-response effect on flow-mediated dilation or blood pressure at any dose tested.9 The absence of a dose-response relationship at these higher doses is an important caution against assuming more is always better.
Honest appraisal: The 2025 meta-analysis provides the most rigorous current synthesis and supports a clinically meaningful effect on systolic blood pressure in persons with elevated readings. However, the evidence base is still limited by small sample sizes across the included trials, and the diastolic and dose-response data are inconsistent. Hawthorn should not be used as a replacement for physician-directed blood pressure management.
Safety, Side Effects, and Drug Interactions
General tolerability
Across dozens of clinical trials, hawthorn extracts have demonstrated a consistently favorable tolerability profile. Adverse events in controlled trials are infrequent, mild, and transient. The most commonly reported side effects include nausea, dizziness, vertigo, palpitations, and mild gastrointestinal discomfort, and these have generally occurred at rates comparable to placebo.7 Even in the large SPICE trial over 24 months, adverse event rates were comparable between hawthorn and placebo groups.2
Drug interactions: consult your physician before combining
- Cardiac glycosides (digoxin): Hawthorn and digoxin may have overlapping effects on myocardial contractility and heart rate. Combining them without medical supervision raises the risk of additive or unpredictable effects on cardiac function.
- Antihypertensive medications: Hawthorn's potential blood pressure-lowering activity may add to the effect of ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, or diuretics, potentially producing excessive blood pressure reduction.
- Nitrates (for angina): Overlapping vasodilatory mechanisms make a theoretical interaction with nitrate medications possible.
- PDE5 inhibitors (sildenafil, tadalafil): Additive vasodilatory effects are theoretically possible; caution is warranted.
- Other prescribed heart medications: Anyone managing a diagnosed cardiovascular condition should speak with their cardiologist or prescribing physician before adding hawthorn to their regimen.
Pregnancy, breastfeeding, and vulnerable populations
Safety data during pregnancy and breastfeeding are insufficient to establish a safety profile. Hawthorn has historically been categorized as potentially uterotonic in some traditional medicine literature, and it should be avoided during pregnancy unless under direct medical supervision. Breastfeeding mothers should also avoid use due to the absence of safety data in this population.
Children and adolescents should not use hawthorn without medical guidance, as no pediatric safety data from clinical trials exist.
Time to effect and long-term use
Clinical trials suggest that meaningful effects may take 4 to 8 weeks of consistent use to become apparent. The SPICE trial documented no significant increase in adverse events even over 24 months of continuous use at 900 mg/day, which is reassuring for medium-term safety, though very long-term data beyond two years remain limited in the published literature.
Hawthorn Berry: Dosage Reference from Clinical Trials
The doses below reflect the ranges studied in the clinical trials cited in this article. All trials used standardized extracts (most commonly WS 1442, standardized to 18.75% OPCs). Raw berry powder and non-standardized products have not been evaluated in these trials and cannot be assumed to deliver equivalent effects.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| Adjunctive cardiac performance support (NYHA II) | 900 mg/day WS 1442 | Divided doses, typically morning and evening, with food | Most common dose in RCTs; the Pittler 2003 meta-analysis pooled trials using this range |
| Adjunctive cardiac support (NYHA III, advanced) | 1800 mg/day WS 1442 | Divided doses with meals | Outperformed 900 mg and placebo for workload in the Tauchert 2002 trial; this dose requires physician oversight |
| Blood pressure support (research range) | 500 to 1200 mg/day standardized extract | Daily with food | Based on the range across trials in the 2025 Szikora meta-analysis; optimal dose not yet established |
| General cardiovascular support | 160 to 900 mg/day standardized extract | Daily with food | Commonly cited range in the broader literature; look for products standardized to OPC or flavonoid content, not just raw weight |
None of these doses constitute medical advice. Anyone with a diagnosed cardiovascular condition, hypertension, or cardiac arrhythmia should discuss hawthorn use with their physician or cardiologist before starting supplementation.
What the Evidence Shows at a Glance
Summary of the primary outcomes studied in clinical trials of hawthorn berry extract, with the strength of the available evidence.
| Outcome | Population Studied | Key Finding | Evidence Strength |
|---|---|---|---|
| Exercise capacity in heart failure (NYHA II-III) | 8 RCTs, 632 patients (Pittler meta-analysis) | +7 W maximal workload vs. placebo (p less than 0.01) | Tier A: Meta-analysis of RCTs |
| Cardiac events and mortality (heart failure) | 2,681 patients over 24 months (SPICE trial) | Primary endpoint not significant; subgroup with LVEF at least 25% showed reduced sudden cardiac death | Tier A: Large RCT; primary endpoint not met |
| Systolic blood pressure | 6 RCTs, 428 patients (Szikora 2025 meta-analysis) | -6.65 mmHg vs. placebo (statistically significant) | Tier A: Meta-analysis of RCTs |
| Diastolic blood pressure | 6 RCTs, 428 patients (Szikora 2025 meta-analysis) | -7.19 mmHg trend; not statistically significant | Tier A: Meta-analysis; result inconclusive |
| Symptom relief (dyspnea, fatigue) in CHF | Multiple RCTs | Significant improvement vs. placebo in multiple trials | Tier A: Multiple RCTs |
| Flow-mediated dilation (nitric oxide pathway) | 21 prehypertensive adults (Asher 2012) | No dose-response effect detected at 1000 to 2500 mg | Tier A: RCT; mechanism not confirmed via NO pathway |
Tier A = evidence from human RCTs or meta-analyses of RCTs. A Tier A rating reflects study design quality, not certainty of benefit.
Frequently Asked Questions
What is hawthorn berry good for?
Hawthorn berry is most studied for supporting cardiac performance in people with mild-to-moderate heart failure (as an add-on to standard care) and for supporting healthy blood pressure. A meta-analysis of 8 trials in 632 patients found a mean 7-Watt improvement in exercise capacity over placebo. It is not a treatment for any disease.
How much hawthorn berry should I take per day?
Clinical trials have primarily used 900 mg/day of WS 1442 extract (standardized to 18.75% OPCs) for cardiac support, divided into two doses. For blood pressure, trials have used 250 to 1200 mg/day. The optimal dose is not definitively established. Always choose products standardized to OPC or flavonoid content.
Is hawthorn berry safe to take daily?
Clinical trials lasting up to 24 months report that hawthorn is generally well-tolerated, with side effects including mild nausea, dizziness, and gastrointestinal discomfort occurring at rates similar to placebo. However, hawthorn carries meaningful drug interaction potential, particularly with heart medications, and should not be taken daily without physician awareness if you have cardiovascular disease.
Does hawthorn berry lower blood pressure?
Research suggests it may help. A 2025 meta-analysis of six randomized trials in 428 participants found hawthorn reduced systolic blood pressure by 6.65 mmHg versus placebo, a statistically significant result. The diastolic reduction did not reach significance. Hawthorn should not replace physician-directed antihypertensive therapy.
Can hawthorn berry help with heart failure symptoms?
Clinical research in patients with mild-to-moderate heart failure (NYHA classes II and III) consistently shows hawthorn extract, used alongside standard medications, may support exercise capacity and reduce symptoms like shortness of breath and fatigue. It is studied as an adjunct, not a replacement, for prescribed heart failure therapy.
What are the side effects of hawthorn berry?
In clinical trials, adverse effects are uncommon and mild. The most reported include nausea, dizziness, vertigo, palpitations, and mild gastrointestinal discomfort, generally comparable to placebo in frequency. More serious risks relate to drug interactions, particularly with digoxin and blood pressure medications, rather than direct toxicity.
How long does hawthorn berry take to work?
Clinical trial data suggest that measurable effects on exercise capacity and blood pressure may take 4 to 8 weeks of consistent daily use to become apparent. Trials in the Pittler 2003 meta-analysis ranged from 8 to 24 weeks. Do not expect immediate results, and do not discontinue prescribed medications while waiting to assess hawthorn's effect.
Can hawthorn berry interact with my heart medications?
Yes, and this is the most clinically important caution. Hawthorn may have additive effects with digoxin (cardiac glycoside), antihypertensive drugs, nitrates, and PDE5 inhibitors. Anyone on prescribed heart or blood pressure medication should consult their physician or cardiologist before adding hawthorn to their supplement regimen.
Is WS 1442 the same as hawthorn berry?
WS 1442 is a specific standardized extract of Crataegus leaves and flowers (not just berries) containing 18.75% oligomeric procyanidins. It is the form used in most published clinical trials. Generic hawthorn berry products may have very different constituent profiles and cannot be assumed to deliver equivalent results to what was tested in trials.
Who should not take hawthorn berry?
Hawthorn should be avoided during pregnancy (potential uterotonic effects), by breastfeeding mothers (insufficient safety data), and by children without medical guidance. People with diagnosed cardiovascular conditions, arrhythmias, or those taking heart medications must consult a physician before use due to meaningful drug interaction risk.
Shop Hawthorn Berry
HealthFare Hawthorn Berry supplements
Scientific References
- 1.Pittler MH, Schmidt K, Ernst E Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. American Journal of Medicine. 2003. PubMed: 12798455Clinical (RCT / meta-analysis)
- 2.Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. European Journal of Heart Failure. 2008. PubMed: 19019730Clinical (RCT / meta-analysis)
- 3.Degenring FH, Suter A, Weber M, Saller R A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II. Phytomedicine. 2003. PubMed: 12833999Clinical (RCT / meta-analysis)
- 4.Tauchert M Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. American Heart Journal. 2002. PubMed: 12040357Clinical (RCT / meta-analysis)
- 5.Szikora Z, Matyus RO, Vargane Szabo B, Csupor D, Toth B Hawthorn (Crataegus spp.) Clinically Significantly Reduces Blood Pressure in Hypertension: A Meta-Analysis of Randomized Placebo-Controlled Clinical Trials. Pharmaceuticals (Basel). 2025. PubMed: 40732315Clinical (RCT / meta-analysis)
- 6.Walker AF, Marakis G, Morris AP, Robinson PA Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension. Phytotherapy Research. 2002. PubMed: 11807965Clinical (RCT / meta-analysis)
- 7.Tassell MC, Kingston R, Gilroy D, Lehane M, Furey A Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease. Pharmacognosy Reviews. 2010. PubMed: 22228939Human observational
- 8.Wang J, Xiong X, Feng B Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evidence-Based Complementary and Alternative Medicine. 2013. PubMed: 24459528Human observational
- 9.Asher GN, Viera AJ, Weaver MA, Dominik R, Caughey M, Hinderliter AL Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial. BMC Complementary and Alternative Medicine. 2012. PubMed: 22458601Clinical (RCT / meta-analysis)
- 10.Zapfe jun G Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine. 2001. PubMed: 11515715Clinical (RCT / meta-analysis)
- 11.Leuchtgens H Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study. Fortschritte der Medizin. 1993. PubMed: 8375791Clinical (RCT / meta-analysis)